Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.

MLA

Rowinsky, Eric K., et al. “Phase 1 Study of the Protein Deubiquitinase Inhibitor VLX1570 in Patients with Relapsed and/or Refractory Multiple Myeloma.” Investigational New Drugs, vol. 38, no. 5, Oct. 2020, pp. 1448–53. EBSCOhost, https://doi.org/10.1007/s10637-020-00915-4.

APA

Rowinsky, E. K., Paner, A., Berdeja, J. G., Paba-Prada, C., Venugopal, P., Porkka, K., Gullbo, J., Linder, S., Loskog, A., Richardson, P. G., & Landgren, O. (2020). Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Investigational New Drugs, 38(5), 1448–1453. https://doi.org/10.1007/s10637-020-00915-4

Chicago

Rowinsky, Eric K, Agne Paner, Jesus G Berdeja, Claudia Paba-Prada, Parameswaran Venugopal, Kimmo Porkka, Joachim Gullbo, et al. 2020. “Phase 1 Study of the Protein Deubiquitinase Inhibitor VLX1570 in Patients with Relapsed and/or Refractory Multiple Myeloma.” Investigational New Drugs 38 (5): 1448–53. doi:10.1007/s10637-020-00915-4.